• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    RBC Capital Mkts initiated coverage on Jasper Therapeutics with a new price target

    3/28/24 7:43:51 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JSPR alert in real time by email
    RBC Capital Mkts initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $70.00
    Get the next $JSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JSPR

    DatePrice TargetRatingAnalyst
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    7/8/2024$90.00Buy
    BTIG Research
    6/27/2024$86.00Buy
    Stifel
    5/6/2024$65.00Buy
    H.C. Wainwright
    4/3/2024$65.00Outperform
    Evercore ISI
    3/28/2024$70.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $JSPR
    SEC Filings

    See more
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      6/16/25 6:19:34 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Jasper Therapeutics Inc.

      DEFA14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:02:13 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Jasper Therapeutics Inc.

      DEF 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:00:17 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Carlyle Group Inc. bought $2,460,500 worth of Voting Common Stock (190,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/12/24 6:23:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Velan Capital Investment Management Lp bought $4,532,500 worth of shares (350,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/9/24 8:40:05 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiggans Thomas G bought $6,486 worth of Voting Common Stock (10,000 units at $0.65), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      11/30/23 4:05:16 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care